Peptide lexicon
Cagrilintid
Long-acting, lipidated analogue of the pancreatic hormone amylin and non-selective agonist at amylin and calcitonin receptors.
| Substance class | Peptide |
|---|---|
| CAS number | 1415456-99-3 |
| Molecular formula | C₁₉₄H₃₁₂N₅₄O₅₉S₂ |
| Molar mass | 4,409 g/mol |
| Synonyms | NN9838, langwirksames Amylin-Analogon |
| PubChem | CID 171397054 |
Structure
Cagrilintide is an acylated amylin analogue that reaches a half-life of several days through albumin binding. It activates amylin receptors (calcitonin receptor with RAMP proteins) and the calcitonin receptor itself.
State of research
Cagrilintide is being studied clinically alone and in combination with semaglutide. Preclinical and clinical work addresses satiety signalling, gastric emptying and glucagon secretion.
Status
There is no marketing authorisation. At Peptidkauf it is available as cagrilintide; the lab report identifies it as cagrilintide.
Literature
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysisBMJ, 2024 · PMID 38286487 · DOI 10.1136/bmj-2023-076410
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-AnalysisIndian J Endocrinol Metab, 2024 · PMID 39676787 · DOI 10.4103/ijem.ijem_45_24
- Novel GLP-1-based Medications for Type 2 Diabetes and ObesityEndocr Rev, 2026 · PMID 41054801 · DOI 10.1210/endrev/bnaf036
- Amylin, Another Important Neuroendocrine Hormone for the Treatment of DiabesityInt J Mol Sci, 2024 · PMID 38338796 · DOI 10.3390/ijms25031517
- Beyond weight loss: multisystem benefits of obesity medicationsLancet Diabetes Endocrinol, 2026 · PMID 42208956 · DOI 10.1016/S2213-8587(26)00100-2
